A chimeric poxvirus with J2R (thymidine kinase) deletion shows safety and anti-tumor activity in lung cancer models

[1]  B. Moss,et al.  Inhibition of the complement cascade by the major secretory protein of vaccinia virus. , 1990, Science.

[2]  A. Epstein,et al.  Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy , 2013, Journal of immunotherapy.

[3]  J. Diallo,et al.  The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in Cancers , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  G. Silvestri,et al.  A review of clinical practice guidelines for lung cancer. , 2013, Journal of thoracic disease.

[5]  Qian Zhang,et al.  The highly attenuated oncolytic recombinant vaccinia virus GLV-1h68: comparative genomic features and the contribution of F14.5L inactivation , 2009, Molecular Genetics and Genomics.

[6]  R. Wong,et al.  Oncolytic vaccinia therapy of squamous cell carcinoma , 2009, Molecular Cancer.

[7]  H. Kaufman,et al.  Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy , 2016, Journal of Immunotherapy for Cancer.

[8]  D. Mahoney,et al.  Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum , 2013, International journal of cancer.

[9]  D. Kirn,et al.  Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. , 2007, The Journal of clinical investigation.

[10]  C. Tannenbaum,et al.  Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series , 2018, Journal of Immunotherapy for Cancer.

[11]  H. Atkins,et al.  Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors , 2010, PloS one.

[12]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[13]  Jianrong Zhang,et al.  Updated statistics of lung and bronchus cancer in United States (2018). , 2018, Journal of thoracic disease.

[14]  J. Foloppe,et al.  Vaccinia Virus Shuffling: deVV5, a Novel Chimeric Poxvirus with Improved Oncolytic Potency , 2018, Cancers.

[15]  D. Johnson,et al.  Locally advanced, unresectable non-small cell lung cancer: new treatment strategies. , 2000, Chest.

[16]  S. Workenhe,et al.  Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  L. Zitvogel,et al.  Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy , 2016, Oncoimmunology.

[18]  E. Sonnhammer,et al.  Kalign2: high-performance multiple alignment of protein and nucleotide sequences allowing external features , 2008, Nucleic acids research.

[19]  B. Moss,et al.  Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Y. Yatabe,et al.  Surgery for NSCLC in the era of personalized medicine , 2013, Nature Reviews Clinical Oncology.

[21]  Troy Guthrie,et al.  Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Laurence Zitvogel,et al.  Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.

[23]  D. Tscharke,et al.  A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. , 2002, The Journal of general virology.

[24]  H. Fukuhara,et al.  Oncolytic virus therapy: A new era of cancer treatment at dawn , 2016, Cancer science.

[25]  B. Moss,et al.  Transient dominant selection of recombinant vaccinia viruses , 1990, Journal of virology.

[26]  B. Moss.  Poxvirus DNA replication. , 2013, Cold Spring Harbor perspectives in biology.

[27]  Y. Fong,et al.  Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose , 2018, Journal of Translational Medicine.

[28]  D. Green,et al.  Immunogenic and tolerogenic cell death , 2009, Nature Reviews Immunology.

[29]  M. Bloomston,et al.  Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.

[30]  P. Hauser,et al.  Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression , 2014, PloS one.

[31]  D. Bartlett,et al.  Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity , 2014, Front. Oncol..

[32]  B. Moss,et al.  The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. , 2005, Cancer research.

[33]  Bin Zhou,et al.  Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9 , 2017, Oncotarget.

[34]  A. Alcamí,et al.  Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species soecificity , 1995, Cell.

[35]  C. Thirukkumaran,et al.  Current Immunotherapeutic Strategies to Enhance Oncolytic Virotherapy , 2017, Front. Oncol..

[36]  M. Croft,et al.  Preferential replication of vaccinia virus in the ovaries is independent of immune regulation through IL-10 and TGF-β. , 2011, Viral immunology.

[37]  L. Zitvogel,et al.  Calreticulin exposure dictates the immunogenicity of cancer cell death , 2007, Nature Medicine.

[38]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[39]  Y. Nakanishi,et al.  Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. , 2012, Cancer research.

[40]  D. Kirn,et al.  Efficacy and Safety/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  Geoffrey L. Smith,et al.  Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus , 1996, Journal of virology.

[42]  Y. Fong,et al.  Recombinant vaccinia virus GLV-1h68 is a promising oncolytic vector in the treatment of cholangiocarcinoma , 2015, Cancer Gene Therapy.

[43]  M. Lusky,et al.  Immunogenicity of oncolytic vaccinia viruses JX-GFP and TG6002 in a human melanoma in vitro model: studying immunogenic cell death, dendritic cell maturation and interaction with cytotoxic T lymphocytes , 2017, OncoTargets and therapy.

[44]  D. Tscharke,et al.  A study of the vaccinia virus interferon-γ receptor and its contribution to virus virulence , 2002 .

[45]  A. Ristimäki,et al.  Antiangiogenic Arming of an Oncolytic Vaccinia Virus Enhances Antitumor Efficacy in Renal Cell Cancer Models , 2009, Journal of Virology.

[46]  Y. Fong,et al.  A Novel Oncolytic Chimeric Orthopoxvirus Encoding Luciferase Enables Real-Time View of Colorectal Cancer Cell Infection , 2018, Molecular therapy oncolytics.

[47]  K. Partanen,et al.  Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  D. Bartlett,et al.  Oncolytic viruses as therapeutic cancer vaccines , 2013, Molecular Cancer.